Clinical Trial: NCT05319015
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | University of Texas Southwestern Medical Center |
| Information Provided By: | University of Texas Southwestern Medical Center |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
Official Title
A Phase II Study of the Safety and Efficacy of Neoadjuvant Lenvatinib and Pembrolizumab in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus
Conditions
Renal Cell Carcinoma
Intervention / Treatment
- Drug: Neoadjuvant Lenvatinib
- Drug: Neoadjuvant Pembrolizumab
- Procedure: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
- Drug: Adjuvant Pembrolizumab
Other Study ID Numbers
- STU-2021-1240
Start Date (Actual)
2023-01-06
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
30
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | University of Texas Southwestern Medical Center |
| Information Provided By: | University of Texas Southwestern Medical Center |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
Official Title
A Phase II Study of the Safety and Efficacy of Neoadjuvant Lenvatinib and Pembrolizumab in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus
Conditions
Renal Cell Carcinoma
Intervention / Treatment
- Drug: Neoadjuvant Lenvatinib
- Drug: Neoadjuvant Pembrolizumab
- Procedure: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
- Drug: Adjuvant Pembrolizumab
Other Study ID Numbers
- STU-2021-1240
Start Date (Actual)
2023-01-06
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
30
Study Type
Interventional
Phase
Phase 2